1. Gottlieb JA, Guarino AM, Call JB, Oliverio VT, Block JB (1970) Preliminary pharmacologic and clinical evaluation of camptothecin sodium (NSC 100880). Cancer Chemother Rep 54:461–470
2. Muggia FM, Creven PJ, Hansen HH, Cohen MH, Selawry OS (1972) Phase I clinical trial of weekly and daily treatment with camptothecin (NSC 100880). Cancer Chemother Rep 56:515–521
3. Moertel CG, Schutt AJ, Reitmeier RJ, Hahn RG (1972) Phase II study of camptothecin (NSC 100880) in the treatment of advanced gastrointestinal cancer. Cancer Chemother Rep 56:95–101
4. Bleiberg H, Rothenberg ML (1996) CPT-11: from DNA topology to clinical activity. Semin Oncol 23:1–50
5. Kolimannsberger C, Mross K, Jakob A, Kanz L, Bokemyer C (1999) Topotecan—a novel topoisomerase I inhibitor: pharmacology and clinical experience. Oncology 56:1–12